Envoy Medical, Inc. filings document a hearing-health company with Class A common stock and redeemable warrants listed on Nasdaq. Its regulatory record covers operating results, financial-condition updates, registration statements for securities offerings, warrant and pre-funded warrant structures, and disclosures related to its status as an emerging growth company.
Company filings also include proxy materials for director elections, auditor ratification, executive compensation, equity incentive and employee stock purchase plan amendments, and Nasdaq share-issuance approvals. Form 8-K disclosures address material agreements, auditor changes, compensatory arrangements, Nasdaq listing compliance, and risk-related matters such as going-concern language in audit reports.
Envoy Medical, Inc. stockholders approved an amendment authorizing the Board of Directors, at its discretion, to effect one or more reverse stock splits of Class A common stock at a ratio from 1-for-5 to 1-for-25, at any time through December 31, 2026. The first proposal received 44,012,206 votes for, 50,668 against and 1,872 abstentions.
Stockholders also approved an adjournment proposal to allow time to gather votes for the Issuance Proposal or ensure a quorum; that authority was not used. The second proposal received 43,642,799 votes for, 406,221 against and 15,726 abstentions.
Envoy Medical, Inc. (COCH) entered into a Dismissal Agreement with Atlas Merchant Capital SPAC Fund I LP on October 6, 2026, concerning litigation in the Delaware Court of Chancery. Under the agreement, all of Atlas’ claims will be dismissed with prejudice, and there will be no further proceedings. Envoy Medical and the other defendants are not required to make a payment to Atlas under the agreement.
Envoy Medical, Inc. (COCH) reports in this Schedule 13G/A Amendment No. 1 that Alta Partners LLC beneficially owns 2,054,011 shares of Class A common stock, all issuable upon exercise of warrants. This position represents 2.59% of the Class A common stock, with sole voting and dispositive power over all such shares.
Alta Partners LLC reports no shared voting or dispositive power and confirms that its ownership is 5 percent or less of the class. The filing is signed by Steven Cohen as Managing Member on September 14, 2026.
Envoy Medical, Inc. (COCH) is asking stockholders at an October 12, 2026 special meeting to approve an amendment authorizing the Board, at its discretion, to implement one or more reverse stock splits of the Class A common stock within a 1‑for‑5 to 1‑for‑25 range any time through December 31, 2026. As of August 19, 2026, there were 77,394,595 Class A shares outstanding and entitled to vote.
The stated primary goal is to regain compliance with Nasdaq’s $1.00 minimum bid price requirement after Envoy received deficiency notices and a final compliance deadline of November 16, 2026. The split would not change authorized share counts or par value, and fractional shares would be cashed out. Envoy warns that the split may not sustain a higher price, could reduce liquidity, and failure to lift and maintain the price above $1.00 could lead to Nasdaq delisting, limiting access to capital. A second proposal would allow adjournment of the meeting to solicit additional proxies if needed.
Envoy Medical, Inc. (COCH) appointed Robert Potashnick as Chief Accounting Officer and Vice President of Finance, effective August 24, 2026. He will continue to serve as the company’s principal financial officer and principal accounting officer, transitioning from his prior contractor role as Interim Chief Financial Officer.
Under an Employment Agreement dated August 24, 2026, Mr. Potashnick will receive a base salary of $315,000 per year, an initial target annual bonus equal to 15% of base salary based on performance goals, and an initial equity award of 250,000 stock options with an exercise price of $0.746 per share, matching the Class A common stock closing price on his hire date. The agreement includes six months of severance compensation in certain termination scenarios. The company states he has no related-party transactions requiring disclosure and no family relationships with directors or executive officers.
Envoy Medical, Inc. (COCH) reported that officer Robert Potashnick, CAO & VP of Finance, received a grant of 250,000 stock options on 2026-08-24 with an exercise price of $0.746 per share, expiring on 2036-08-24. According to the vesting terms, options to purchase 62,500 shares vest on 2027-08-24 and the remaining 187,500 shares vest pro rata on the 24th of each month thereafter for 36 months.
Potashnick also has an existing option covering 15,000 underlying shares at a $0.53 exercise price, plus direct holdings of 212,500 shares of Class A common stock. In addition, he holds warrants exercisable for 127,500 and 212,500 Class A shares at a $0.40 exercise price, which become exercisable upon shareholder approval and have expirations tied to key FDA milestones for Envoy Medical’s Acclaim CI Device.
Envoy Medical, Inc. (COCH) is asking stockholders to approve an amendment allowing its board to execute one or more reverse stock splits of the Class A common stock, at a ratio between 1‑for‑5 and 1‑for‑25, any time up to December 31, 2026. The main objective is to raise the share price to regain compliance with Nasdaq’s $1.00 Minimum Bid Price Requirement and preserve the Nasdaq Capital Market listing ahead of a November 16, 2026 compliance deadline. A separate proposal would permit adjournment of the special meeting to solicit additional votes if needed. A reverse split would proportionally reduce the 77,194,595 shares outstanding but leave authorized capital (400 million Class A, 100 million preferred) and percentage ownership essentially unchanged, with cash paid in lieu of fractional shares. The board would retain discretion on whether and at what exact ratio to implement the split, and it warns that failure to regain compliance could lead to Nasdaq delisting and reduced access to capital.
Envoy Medical, Inc. reported second-quarter 2026 results and highlighted progress toward commercializing its fully implanted Acclaim cochlear implant. The company submitted the first of four modules of its modular PMA application to the FDA and plans to submit remaining modules on a rolling basis, with the fourth targeted in the second quarter of 2027. Subsequent to quarter end, Envoy reported positive 12‑month data for the first 10 Stage 1 trial participants and noted that the pivotal trial has surpassed the three‑month follow-up mark.
For the quarter ended June 30, 2026, net revenue was $51,000. Net loss attributable to common stockholders was $7.3 million, or $0.07 per share. As of June 30, 2026, cash was $19.7 million, supported by $30.0 million of proceeds from an issuance of Class A common stock, pre‑funded warrants and Series A warrants during the first half of 2026. Total assets were $23.9 million and stockholders’ equity was $3.3 million.
Envoy Medical, Inc. develops fully implanted hearing devices and remains a pre-revenue, development-stage company centered on its investigational Acclaim cochlear implant. For the three and six months ended June 30, 2026, it generated only $51k and $90k of net revenue, respectively, primarily from legacy Esteem implant components, while recording net losses of $5.98M and $10.33M.
Research and development spending was substantial at $3.13M for the quarter and $6.77M year-to-date, driving an operating loss of $11.53M for the first half. Operating cash outflow was $11.52M, but cash increased to $19.68M at June 30, 2026 from $3.74M at year-end, mainly due to the February 2026 equity offering, which raised $29.997M gross and $27.78M net and expanded Class A shares outstanding to 77.2M. Numerous warrants and preferred shares create a sizable potential dilution overhang.
Management explicitly states that existing cash is not sufficient to fund operations for 12 months after issuance of these financial statements, concluding that substantial doubt exists about the company’s ability to continue as a going concern. Plans rely on additional financing and potential warrant exercises. Clinically, all 56 pivotal Acclaim cochlear implant trial participants have been enrolled and activated, the first 10 have reached 12-month follow-up, all 56 have passed the 3‑month milestone, and the first module of the Premarket Approval application was submitted to the FDA.
Envoy Medical, Inc. has terminated its at-the-market equity facility, which had allowed the company to offer and sell up to $15 million of common stock from time to time. The termination, effective June 24, 2026, also ends the related At The Market Offering Agreement dated January 17, 2025.
The company framed this step as reflecting confidence in its current capital position. Existing Class A common stock and redeemable warrants continue to trade on Nasdaq under the symbols COCH and COCHW, respectively.